Project Grant R01CA287126
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$655K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This $961,118 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The Johns Hopkins University to target gut bacterial androgen production in order to reverse abiraterone resistance in metastatic prostate cancer. The 3-year award, beginning September 1, 2024, will enable the university to conduct innovative scientific studies aimed at developing treatments to improve health outcomes for...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $271,697 Project Grant to The Johns Hopkins University on Sep 1, 2024. The grant funds research to "TARGET GUT BACTERIAL ANDROGEN PRODUCTION TO REVERSE ABIRATERONE RESISTANCE IN METASTATIC PROSTATE CANCER". This research aims to develop new treatments for metastatic prostate cancer by investigating the role of gut bacteria in androgen production and resistance to certain cancer...
This federal Project Grant award, ID HT94252410076, was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to The Johns Hopkins University. The $163,750 award, granted on February 1, 2024, will support research examining the influence of the gut microbiome on drug metabolism and treatment resistance in prostate cancer, with a completion date of January 31, 2026. As a leading research institution, The Johns Hopkins...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,473,751.00 to The Johns Hopkins University to conduct research on the influence of the tumor immune microenvironment and microbiome on prostate cancer immunotherapy response in Black men. The award period runs from August 15, 2024 through August 15, 2027. The research aims to improve understanding of how the unique tumor and microbial factors present in...
This $530,612 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to investigate the role of the gut microbiome in melanoma progression and prevention of lymph node metastasis. The key research objectives are to: 1) Identify gut microbial and immunologic features associated with tumor progression and lymph node metastasis in melanoma patients, and 2) Determine strategies to modulate the gut microbiome to prevent melanoma progression and...
This $421,042 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports a study of IDH1-mutant prostate cancer to identify novel therapeutic targets. The primary objectives are to investigate the mechanisms by which IDH1-mutant prostate cancer fails to acquire resistance to therapy, with the goal of identifying new treatment approaches to prevent resistance development. The study will involve analyzing clinical, genomic,...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $179,988 to The Leland Stanford Junior University to support research aimed at modulating the human microbiome to enhance immune responses against cancer. The central hypothesis is that microbial functional features, rather than just compositional differences, underlie the impact of the gut microbiome on the efficacy of immune checkpoint blockade cancer immunotherapy. The...
The National Cancer Institute (NCI) awarded a five-year, $626,893 Project Grant (CFDA 93.396 - Cancer Biology Research) to The University of Texas MD Anderson Cancer Center to investigate the role of bacterial-colonized microniches within tumors and their impact on intratumoral heterogeneity and cancer progression. The project aims to functionally map the cellular and metabolic features of these bacterial-colonized microniches in patient tumor tissues, delineate the human cell types harboring...
This Project Grant award for $138,240 from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) will fund research at Weill Medical College of Cornell University to define novel mechanisms by which the microbiota (gut microbes) regulate anti-tumor immune responses and immunotherapy outcomes. The research aims to elucidate how host-microbiota interactions promote tumor growth and progression, as well as shape systemic anti-tumor immunity and response to...
This $678,399 Project Grant award was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program to The University of Texas MD Anderson Cancer Center. The funding will support a research study to evaluate the impact of a prebiotic diet intervention combined with standard immune checkpoint inhibitor (ICI) therapy in patients with metastatic melanoma.
The study aims to investigate whether the prebiotic diet intervention can modulate the...